Nursing and Health Professions
Patient
100%
Tensin
56%
Phosphatase
56%
Epidermal Growth Factor Receptor 2
31%
Combination Therapy
12%
Stomach Cancer
12%
Trastuzumab
12%
Phosphatidylinositol 3 Kinase
12%
Lapatinib
12%
Diseases
6%
Biological Marker
6%
Survival Time
6%
Progression Free Survival
6%
Combination Drug
6%
Procedures
6%
Time
6%
Immunohistochemistry
6%
Pyrosequencing
6%
Combination Chemotherapy
6%
Medicine and Dentistry
Phosphatase
56%
Tensin
56%
Gamma Urogastrone
31%
Epidermal Growth Factor Receptor 2
31%
Combination Therapy
12%
Phosphoinositide 3-Kinase
12%
Trastuzumab
12%
Lapatinib
12%
Targeted Therapy
12%
Therapeutic Procedure
12%
Diseases
6%
Biological Marker
6%
Survival Time
6%
Development
6%
Progression Free Survival
6%
Predictive Marker
6%
Combination Chemotherapy
6%
Pharmacology, Toxicology and Pharmaceutical Science
Phosphatase
56%
Tensin
56%
Epidermal Growth Factor Receptor 2
31%
Gamma Urogastrone
31%
Phosphatidylinositol 3 Kinase
12%
Stomach Cancer
12%
Trastuzumab
12%
Lapatinib
12%
Diseases
6%
Biological Marker
6%
Progression Free Survival
6%
Survival Time
6%
Biochemistry, Genetics and Molecular Biology
Phosphatase
56%
Tensin
56%
Epidermal Growth Factor Receptor
31%
Mutation
12%
Phosphoinositide 3-Kinase
12%
Trastuzumab
12%
Lapatinib
12%
Survival Time
6%
Progression Free Survival
6%
Development
6%
Time
6%
Pyrosequencing
6%